PubRank

F Goldwasser

Author PubWeight™ 47.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009 2.06
2 Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006 1.38
3 Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient. Ann Oncol 2009 1.38
4 Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 2011 1.35
5 Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol 2001 1.26
6 Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013 1.26
7 Primary non-Hodgkin's lymphomas of the liver with nodular and diffuse infiltration patterns have different prognoses. Ann Oncol 2001 1.22
8 Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol 2008 1.22
9 Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997 1.18
10 High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 2008 1.17
11 Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 2009 1.16
12 Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol 2007 1.11
13 Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol 2009 1.08
14 The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 1995 1.07
15 Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007 1.05
16 The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of alpha-fetoprotein or beta-human chorionic gonadotrophin: report of two cases. Ann Oncol 2002 1.01
17 Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol 2011 0.97
18 Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 2007 0.97
19 Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999 0.97
20 Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol 2008 0.96
21 Clinical pharmacodynamic factors in docetaxel toxicity. Br J Cancer 2007 0.94
22 Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine. Anticancer Drugs 1999 0.92
23 Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999 0.92
24 Anthracyclines during pregnancy: embryo-fetal outcome in 160 patients. Ann Oncol 2004 0.92
25 Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 2008 0.91
26 Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol 2003 0.91
27 Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 2009 0.90
28 Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 2006 0.88
29 Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 2001 0.88
30 Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form. Int J Cancer 2010 0.88
31 [Adamantinoma of the proximal end of the tibia. A case]. Presse Med 1994 0.87
32 Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 2009 0.87
33 Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. Br J Cancer 2011 0.87
34 Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients. Eur J Cancer 2002 0.84
35 Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. Invest New Drugs 2014 0.84
36 Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications. Ann Oncol 2011 0.82
37 Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study. Br J Cancer 2011 0.81
38 Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase II beta isoform. Biochem Pharmacol 1995 0.81
39 Sorafenib in advanced melanoma: a critical role for pharmacokinetics? Br J Cancer 2012 0.81
40 Chronotherapy of colorectal cancer metastases. Hepatogastroenterology 2001 0.79
41 Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid. Ann Oncol 2012 0.79
42 Exacerbation of oxaliplatin neurosensory toxicity following surgery. Ann Oncol 2002 0.79
43 [Use of sorafenib in patients with hepatocellular or renal carcinoma]. Gastroenterol Clin Biol 2010 0.78
44 Pregnancy-associated breast cancer is as chemosensitive as non-pregnancy-associated breast cancer in the neoadjuvant setting. Ann Oncol 2011 0.78
45 A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors. Invest New Drugs 2013 0.77
46 Chemotherapy for breast cancer during pregnancy: is epirubicin safe? Ann Oncol 2008 0.77
47 Objective response to sorafenib in advanced clear-cell sarcoma. Ann Oncol 2012 0.77
48 Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient. Anticancer Drugs 2000 0.76
49 Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst 1998 0.75
50 Oxaliplatin in inoperable or metastatic bladder cancer. Ann Oncol 2006 0.75
51 Soluble VEGFR-1: a new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?). J Clin Pharmacol 2014 0.75
52 Paclitaxel (Taxol)-associated junctional tachycardia. Anticancer Drugs 1997 0.75
53 Severe CPT-11-induced diarrhea in presence of FK-506 following liver transplantation for hepatocellular carcinoma. Anticancer Res 2002 0.75
54 [Metastatic eye neoplasms. Review of the literature apropos of 4 cases]. Rev Med Interne 1994 0.75
55 Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11. Anticancer Drugs 2000 0.75
56 [Endometriosis-associated ovarian cancers: pathogenesis and consequences on daily practice]. J Gynecol Obstet Biol Reprod (Paris) 2013 0.75
57 Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. Int J Cancer 1995 0.75